Antidepressant Effects of Mitragyna Speciosa Korth Extract on Diabetic Rats
Article Sidebar
Main Article Content
Abstract
Background: Diabetes mellitus is most common associated with neurological complications, including depressive symptoms, so this study investigated whether mitragyna may provide benefits in reducing depressive symptoms in animal models of diabetes. This study aims to evaluate the effect of mitragyna as a potential antidepressant agent in animal models of diabetes mellitus using the Force Swimming Test (FST).
Methods: In this study, diabetes mellitus rats were induced by administering streptozotocin and then divided into four groups: control group (Control), Group Diabetes (DM), Mitragyna treatment group (DM+EMS 15mg) and (DM+EMS 30mg). After the treatment period, the rats were then tested with the FST, which is used to measure immobility behavior which can be used as an indicator of depressive symptoms.
Results: The results showed that the treatment group that received mitragyna showed shorter immobility times compared to the control group (P<0.01), indicating an increased active response in facing FST stressors.
Conclusion: These results indicate that mitragyna has potential as an antidepressant agent in reducing depressive symptoms in rats models of diabetes mellitus.
Downloads
Article Details
Copyright (c) 2024 Reza Hery Mahendra Putra, Evi Sylvia Awwaliyah, Hotimah Masdan Salim, Ilham Putera Alam, Ainul Rofiq
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
McLaughlin RJ, et al. (2015). Kratom and Other Mitragynines: The Chemistry and Pharmacology of Opioids from a Non-Opium Source. In: Methods in Enzymology, vol 554.
Suhaimi FW, et al. (2016). Neurobiology of Kratom and its main alkaloid mitragynine. Brain Research Bulletin, 126(Pt 1), 29-40.
Zainal NF, et al. (2020). Antidepressant-Like Effects of Mitragynine in Rats: Insights into Serotonergic and Noradrenergic Mechanisms. Journal of Natural Products, 83(2), 424-429.
Semple SJ, et al. (2019). Kratom use and toxicities in the United States. Pharmacotherapy, 39(7), 775-777.
Ciprian-Ollivier J, et al. (1986). Use of the automated measurement of the duration of immobility for the detection of new antidepressants. Psychopharmacology, 90(4), 512-514.
Chen, L., Fei, S., & Olatunji, O. J. (2022). LC/ESI/TOF-MS Characterization, Anxiolytic and Antidepressant-like Effects of Mitragynine Korth Extract in Diabetic Rats. Molecules (Basel, Switzerland), 27(7), 2208. https://doi.org/10.3390/molecules27072208
Idayu, N. F., Hidayat, M. T., Moklas, M. A., Sharida, F., Raudzah, A. R., Shamima, A. R., & Apryani, E. (2011). Antidepressant-like effect of mitragynine isolated from Mitragynine Korth in rats model of depression. Phytomedicine : international journal of phytotherapy and
Correia, A. S., Cardoso, A., & Vale, N. (2023). Oxidative Stress in Depression: The Link with the Stress Response, Neuroinflammation, Serotonin, Neurogenesis and Synaptic Plasticity. Antioxidants, 12(2), 470. https://doi.org/10.3390/antiox12020470